Abstract:The SMYD family is a unique class of lysine methyltransferases (KMTases) known to methylate histones but also non-histone proteins. Among the five SMYD family members (1-5), SMYD1 was identified as a heart- and skeletal muscle-specific KMTase, which, together with Unc45b and Hsp90a, interacts with Myosin thereby regulating thick filament assembly. However, the process by which SMYD1 orchestrates Myosin assembly is largely unknown. Here, we found that SMYD1 physically interacts with Myosin heavy chain (Myh) at its N-terminus and that the Myh N-terminus specifically gets mono-methylated by SMYD1 at lysine 35 (K35). Accordingly, methylated Myh is properly integrated into functional sarcomeres, whereas unmethylated Myh molecules in Smyd1-deficient zebrafish are efficiently degraded by the Ubiquitin Proteasome System (UPS) leading to defective thick filament assembly. Although the inhibition of the UPS by MG132 is able to reconstitute Myosin levels in Smyd1-deficient zebrafish embryos, thick filament assembly is still blocked due to the lack of K35 Myh mono-methylation. Similar to the situation in zebrafish striated muscle cells, SMYD1-mediated MYH methylation is also critical for thick filament assembly in human cardiomyocytes, indicating cross-species conservation of this fundamental mechanism of Myosin methylation, which has been first described about 40 years ago. Further investigations will now be essential to explore the therapeutic potential of targeting this pathway in cardiomyopathies and skeletal muscle disorders.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is **the crucial role of lysine 35 (K35) monomethylation mediated by SMYD1 in myosin heavy chain (MHC) in thick filament assembly in cardiomyocytes and skeletal muscle cells**. Specifically, the researchers want to clarify the following aspects: 1. **Interaction between SMYD1 and myosin**: Confirm whether SMYD1 can directly bind to the N - terminal region of myosin heavy chain (Myh), and whether this binding is crucial for myosin methylation. 2. **Specific methylation sites**: Determine whether SMYD1 specifically performs monomethylation modification at the K35 site of Myh, and whether this modification is conserved in different species. 3. **Effects of methylation on myosin stability and function**: Explore whether methylation at the K35 site is important for the correct folding, stability, and thick filament assembly of myosin, and whether unmethylated myosin will be degraded through the ubiquitin - proteasome system (UPS). 4. **Cross - species conservation**: Verify whether SMYD1 - mediated Myh K35 methylation has the same biological significance in zebrafish and human - induced pluripotent stem cell - derived cardiomyocytes (hiPSC - CMs), thereby demonstrating the evolutionary conservation of this mechanism. 5. **Potential therapeutic significance**: Explore whether SMYD1 - mediated Myh K35 methylation is related to the occurrence and development of diseases such as hypertrophic cardiomyopathy (HCM), and whether this pathway can be a potential target for future treatment of these diseases. Through the answers to these questions, the researchers hope to reveal the physiological function of myosin methylation in muscle cells and its potential role in diseases, providing a theoretical basis for further development of treatment methods for heart and skeletal muscle diseases.

SMYD1-mediated Mono-Methylation of Lysine K35 of the sarcomeric Myosin Heavy Chain (MHC) is fundamental for thick filament assembly in zebrafish and human iPSC-derived cardiomyocytes